Table 1.
Summary of case reports and series of bendamustine-induced immune hemolytic anemia
| Reference/year | n | Age, y/sex | Hematologic diagnosis (n) | No. of bendamustine cycles prior to hemolysis | Prior nonbendamustine purine analog exposure (n) | Low platelets (nadir platelet count) | DAT status | Treatment | Outcome |
|---|---|---|---|---|---|---|---|---|---|
| Cuneo et al7/2018 | 2 | NR | CLL (2) | NR | Fludarabine Chlorambucil |
NR | NR | NR | NR |
| Fischer et al8/2011 | 2 | NR | CLL (2) | NR | Fludarabine Fludarabine |
NR | NR | NR | NR |
| Glance et al9/2009 | 1 | 64/female | FL (1) | 4 | No | Yes (16) | Negative | P 1 mg/kg | Recovered |
| Goldschmidt et al10/2013 | 5 | 69/male63/female66/female59/male54/male | CLL (5) | 1 2 6 1 1 |
Fludarabine Fludarabine Chlorambucil Fludarabine Fludarabine |
NR | IgG+ C3+ Negative IgG+ Negative |
P, R P, R, C P M, I, R, C P, R |
Recovered (4/5) Death (1/5) |
| Haddad et al11/2014 | 1 | 70/female | CLL (1) | 3 | Fludarabine | NR | IgG+, C3+ | P 1 mg/kg | Recovered |
| Hodskins et al12/2014 | 1 | 62/male | CLL (1) | 1 | No | NR | Positive | P | Recovered |
| Knauf et al13/2009 | 2 | NR | CLL (2) | NR | No (2) | NR | NR | NR | NR |
| Laurenti et al14/2016 | 6 | 58/female62/female68/male64/female63/female68/male | CLL (6) | 6 4 2 3 4 1 |
No No Fludarabine Fludarabine Fludarabine Chlorambucil |
NR | Positive IgG+ Positive Negative Negative IgG+ |
P P P, R, C, V R P P |
Recovered (6/6) |
| Nyatanga et al15/2015 | 5 | 63 (median)56-69 (range) | CLL (5) | NR | Fludarabine (3) | NR | NR | P (3) P, R (1) P, R, C (1) |
Recovered (5/5) |
| Spacek et al16/2019 | 1 | NR | CLL (1) | NR | NR | NR | NR | NR | NR |
C, cyclophosphamide; FL, follicular lymphoma; I, IV immunoglobulin; M, methylprednisolone; NR, not reported; P, prednisone; R, rituximab; V, vincristine.